Workflow
Sansure Biotech(688289)
icon
Search documents
圣湘生物:人冠状病毒、副流感病毒、新型冠状病毒核酸检测试剂盒获得医疗器械注册证
南财智讯9月30日电,圣湘生物公告,公司收到国家药品监督管理局颁发的《医疗器械注册证》,产品 名称为人冠状病毒、副流感病毒、新型冠状病毒核酸检测试剂盒(荧光PCR法)。该产品用于体外定性 检测具有新型冠状病毒感染或其他呼吸道感染相关症状人群的咽拭子样本中的人冠状病毒、副流感病毒 和新型冠状病毒的核酸。产品的获批有助于提升感染性疾病诊疗水平,为临床精准用药和抗菌药物管理 提供有力支撑。但产品未来的市场表现存在不确定性。 ...
圣湘生物产品取得医疗器械注册证
Zhi Tong Cai Jing· 2025-09-30 08:15
圣湘生物(688289.SH)发布公告,公司的产品人冠状病毒、副流感病毒、新型冠状病毒核酸检测试剂盒 (荧光PCR法)于近日收到由国家药品监督管理局颁发的《医疗器械注册证》。 公司本次获证的人冠状病毒、副流感病毒、新型冠状病毒核酸检测试剂盒采用多重荧光PCR技术,具备 高灵敏度、高特异性、操作简便等优势,最快可在30分钟内完成3种病原的精准鉴别。该产品可结合公 司现有的呼吸道感染核酸快速检测方案,统一采样、统一扩增,实现多种常见呼吸道病原体同步检测。 该系列产品已覆盖常见呼吸道病毒、细菌、真菌、非典型病原体及耐药基因,广泛适用于门诊、急诊及 住院等多种场景,同时支持基于患者临床表现、地域及季节流行特征,灵活组合不同检测产品,更好应 对多病原共流行和混合感染等复杂局面,为临床精准用药和抗菌药物管理提供有力支撑。 ...
圣湘生物(688289.SH)产品取得医疗器械注册证
智通财经网· 2025-09-30 08:15
智通财经APP讯,圣湘生物(688289.SH)发布公告,公司的产品人冠状病毒、副流感病毒、新型冠状病 毒核酸检测试剂盒(荧光PCR法)于近日收到由国家药品监督管理局颁发的《医疗器械注册证》。 公司本次获证的人冠状病毒、副流感病毒、新型冠状病毒核酸检测试剂盒采用多重荧光PCR技术,具备 高灵敏度、高特异性、操作简便等优势,最快可在30分钟内完成3种病原的精准鉴别。该产品可结合公 司现有的呼吸道感染核酸快速检测方案,统一采样、统一扩增,实现多种常见呼吸道病原体同步检测。 该系列产品已覆盖常见呼吸道病毒、细菌、真菌、非典型病原体及耐药基因,广泛适用于门诊、急诊及 住院等多种场景,同时支持基于患者临床表现、地域及季节流行特征,灵活组合不同检测产品,更好应 对多病原共流行和混合感染等复杂局面,为临床精准用药和抗菌药物管理提供有力支撑。 ...
股权激励板块牛股成群,优质潜力股曝光
Zheng Quan Shi Bao· 2025-09-29 00:01
Core Viewpoint - The implementation of equity incentives has significantly boosted the performance of many companies in the A-share market, with an average increase of over 64% in the equity incentive sector, outperforming major indices like the Shanghai Composite Index and the ChiNext Index [1][2]. Group 1: Performance of Companies - The equity incentive sector has seen 27 stocks more than double in value this year, with New Yisheng leading at a 354.85% increase [1]. - Companies like Nanya New Materials and Zhongji Xuchuang have also shown impressive growth, with revenue increases of over 43% and net profit increases of nearly 58% [1]. - The majority of companies that implemented equity incentives have experienced significant performance improvements, with 88% reporting revenue growth and 76.88% reporting net profit growth [2]. Group 2: Impact of Equity Incentives - Equity incentives align the interests of employees with those of the company, enhancing motivation and innovation, which in turn drives company performance in various areas [2]. - The market perceives companies that implement equity incentives as more confident in their future growth, leading to higher stock valuations [2]. Group 3: Future Growth Potential - Recent data indicates that 63 stocks have implemented equity incentives since September, with many expected to achieve high growth rates in net profit, exceeding 15% in the coming years [3]. - Shaoneng Co., with a low price-to-book ratio of 1.32, is highlighted as a company with significant growth potential in the clean energy sector [3]. - The company has set ambitious performance targets for its equity incentive plan, aiming for a net profit growth rate of at least 30% in 2025 and 97% by 2027 [4][5]. Group 4: Market Trends - The slow bull market in A-shares is creating favorable conditions for investment in the equity incentive sector, with expectations of more quality companies emerging [6]. - The increasing recognition of the importance of equity incentives among companies is likely to lead to more opportunities for investors [6].
医疗器械板块9月26日跌1.68%,锦好医疗领跌,主力资金净流出6.21亿元
从资金流向上来看,当日医疗器械板块主力资金净流出6.21亿元,游资资金净流入1.32亿元,散户资金净 流入4.89亿元。医疗器械板块个股资金流向见下表: | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 688358 | 祥生医疗 | 32.90 | 9.30% | 5.50万 | | 1.77亿 | | 300326 | ST凯利 | 5.88 | 3.70% | 18.20万 | | 1.06亿 | | 688289 | 圣湘生物 | 20.50 | 3.07% | 11.12万 | | 2.27亿 | | 300677 | 英科医疗 | 37.76 | 2.61% | 21.41万 | | 8.11亿 | | 300358 | 楚天科技 | 9.11 | 2.59% | 41.69万 | | 3.76亿 | | 688212 | 澳华内镜 | 49.14 | 2.55% | 1.92万 | | 9322.40万 | | 688026 | 洁特生物 | 18.29 | 1.72 ...
科创增强ETF(588520)开盘涨0.31%,重仓股中芯国际跌0.99%,寒武纪涨0.14%
Xin Lang Cai Jing· 2025-09-23 03:22
Core Viewpoint - The article discusses the performance of the Science and Technology Innovation Enhanced ETF (588520), highlighting its recent market activity and key holdings [1]. Group 1: ETF Performance - The Science and Technology Innovation Enhanced ETF (588520) opened with a gain of 0.31%, priced at 1.310 yuan [1]. - Since its inception on June 27, 2025, the fund has achieved a return of 30.89%, with a one-month return of 6.09% [1]. Group 2: Key Holdings - Major holdings in the ETF include: - Semiconductor Manufacturing International Corporation (down 0.99%) - Cambricon Technologies (up 0.14%) - Jianyuan Technology (up 6.32%) - Transsion Holdings (up 2.38%) - Zhuhai CosMX Battery Co., Ltd. (up 1.21%) - Western Superconducting Technologies (up 0.17%) - Xiangsheng Medical (up 0.81%) - Trina Solar (down 0.31%) - China Railway Signal & Communication Corp (unchanged) - Saintshine Medical (up 0.70%) [1].
圣湘生物(688289) - 圣湘生物科技股份有限公司关于自愿披露相关产品取得医疗器械注册证的公告
2025-09-19 09:15
圣湘生物科技股份有限公司 关于自愿披露相关产品取得医疗器械注册证 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 圣湘生物科技股份有限公司(以下简称"公司"或"圣湘生物")的产品金黄色葡萄 球菌及耐甲氧西林金黄色葡萄球菌核酸检测试剂盒(荧光 PCR 法)于近日收到由国 家药品监督管理局颁发的《医疗器械注册证》,现将相关情况公告如下: 证券代码:688289 证券简称:圣湘生物 公告编号:2025-063 一、产品注册相关情况 二、对公司的影响 抗生素耐药性(AMR)是 21 世纪全球公共卫生面临的重大挑战,据相关数据显 示,每年与耐药相关的死亡病例接近 500 万例,其中,耐甲氧西林金黄色葡萄球菌 (MRSA)作为最具威胁性的耐药病原之一,仅 2019 年就造成全球超过 10 万例死亡。 MRSA 对甲氧西林和所有β-内酰胺类抗生素(如青霉素、头孢菌素等)耐药,具备高 发病率、高死亡率及强传播性,已被世界卫生组织(WHO)列入《2024 年细菌类重 点病原体目录》,以提示全球对其耐药性挑战的高度关注。 与甲氧西林敏 ...
圣湘生物相关产品取得医疗器械注册证
Zhi Tong Cai Jing· 2025-09-19 09:14
Core Viewpoint - Shengxiang Bio (688289.SH) has received a medical device registration certificate from the National Medical Products Administration for its Staphylococcus aureus and Methicillin-resistant Staphylococcus aureus nucleic acid detection kit, indicating a significant regulatory approval for its product line [1] Company Summary - The product is a nucleic acid detection kit using fluorescent PCR method, designed for the qualitative detection of Staphylococcus aureus species-specific fragments and the mecA gene of Methicillin-resistant Staphylococcus aureus in human sputum samples [1]
圣湘生物(688289.SH)相关产品取得医疗器械注册证
智通财经网· 2025-09-19 09:09
智通财经APP讯,圣湘生物(688289.SH)发布公告,公司产品金黄色葡萄球菌及耐甲氧西林金黄色葡萄 球菌核酸检测试剂盒(荧光PCR法)于近日收到由国家药品监督管理局颁发的《医疗器械注册证》。本试 剂盒用于体外定性检测人痰液样本中金黄色葡萄球菌种属特异性片段及耐甲氧西林金黄色葡萄球菌 mecA基因的核酸。 ...
圣湘生物:获医疗器械注册证
Xin Lang Cai Jing· 2025-09-19 09:05
圣湘生物公告,公司产品金黄色葡萄球菌及耐甲氧西林金黄色葡萄球菌核酸检测试剂盒(荧光PCR 法)于近日收到由国家药品监督管理局颁发的《医疗器械注册证》。该试剂盒用于体外定性检测人痰液 样本中金黄色葡萄球菌种属特异性片段及耐甲氧西林金黄色葡萄球菌 mecA 基因的核酸。 ...